5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine
C21H28N8O3S — CID 70682713
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine
5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine (PubChem CID 70682713) has the molecular formula C21H28N8O3S and a molecular weight of 472.58 g/mol. Its IUPAC name is 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine.
Molecular Properties
| Compound Name | 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine |
|---|---|
| PubChem CID | 70682713 |
| Molecular Formula | C21H28N8O3S |
| Molecular Weight | 472.58 g/mol |
| Exact Mass | 472.20 |
| IUPAC Name | 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine |
| SMILES | CS(=O)(=O)N1CCN(Cc2cn3cc(-c4ccc(N)nc4)nc(N4CCOCC4)c3n2)CC1 |
| InChI | InChI=1S/C21H28N8O3S/c1-33(30,31)29-6-4-26(5-7-29)13-17-14-28-15-18(16-2-3-19(22)23-12-16)25-21(20(28)24-17)27-8-10-32-11-9-27/h2-3,12,14-15H,4-11,13H2,1H3,(H2,22,23) |
| InChIKey | FQEWTARJFOWACQ-UHFFFAOYSA-N |
| XLogP | 0.29 |
| TPSA | 122.19 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 472.58 |
| LogP ≤ 5 | 0.29 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 70682713 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.